Clinical Phases I and II – the challenges for API crystallization processes



FREE WEBINAR – Clinical Phases I and II – the challenges for API crystallization processes

Would you like to know what are the challenges for API crystallization processes? And what are the scientific approaches to tackle those challenges? Would you like to know the application of these approaches showcased on drug projects?

Watch a recording of a free webinar brought to you by Sophie Janbon, Director at AstraZeneca. During this session, Sophie addressed Clinical Phases I and II, and the challenges for API crystallization processes.

SPEAKERS

Sophie Janbon - Director at AstraZeneca

Dr. Sophie Janbon is a French citizen, who moved to the UK in 2004 to start a Ph.D. at the School of Chemical Engineering and Analytical Sciences (SCEAS) at the University of Manchester in the group of Prof Roger Davey. Sophie's research topic was understanding crystallization pathways from thermotropic liquid crystalline states. Sophie started a Senior Crystallisation Scientist role at AstraZeneca in December 2007. Her main activity was to develop robust crystallization processes for APIs to provide suitable crystalline form and particle properties for downstream processes including efficient isolation/drying, formulation development, and drug product manufacture. These engineered physical attributes are to ensure patients are supplied with consistent and safe investigational medicines. Sophie was promoted in 2017 to Associate Principal Scientist in Crystallisation Science and then became a Team Manager in 2018 in the Early Development Phase (from pre-Lead Optimisation to Phase IIb). Her team consists of specialists including Biocatalysis, Crystallisation science, Material/Particle Science, and Process Engineering.

The slides of the presentation will be available for download next week under the Publications.

A recording of this webinar can be accessed below.